138 related articles for article (PubMed ID: 9365728)
1. [Antiandrogen withdrawal syndrome in hormone refractory metastatic prostate cancer].
Coutant G; Algayres JP; Dordain ML; Selle F; Le Berruyer PY; Bili H; Daly JP
Rev Med Interne; 1997; 18(9):732-4. PubMed ID: 9365728
[No Abstract] [Full Text] [Related]
2. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Sartor AO; Tangen CM; Hussain MH; Eisenberger MA; Parab M; Fontana JA; Chapman RA; Mills GM; Raghavan D; Crawford ED;
Cancer; 2008 Jun; 112(11):2393-400. PubMed ID: 18383517
[TBL] [Abstract][Full Text] [Related]
3. Antiandrogen withdrawal syndrome with nilutamide.
Huan SD; Gerridzen RG; Yau JC; Stewart DJ
Urology; 1997 Apr; 49(4):632-4. PubMed ID: 9111642
[TBL] [Abstract][Full Text] [Related]
4. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
Longmore L; Foley JP; Rozanski TA; Higgins B; Thompson IM
South Med J; 1998 Jun; 91(6):573-5. PubMed ID: 9634122
[TBL] [Abstract][Full Text] [Related]
5. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
6. Antiandrogen withdrawal syndrome with cyproterone acetate.
Sella A; Flex D; Sulkes A; Baniel J
Urology; 1998 Dec; 52(6):1091-3. PubMed ID: 9836560
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy in patients with advanced prostate cancer.
Dreicer R
J Support Oncol; 2010; 8(5):209-11. PubMed ID: 21086878
[No Abstract] [Full Text] [Related]
8. Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.
Asahi H; Mizokami A; Maeda Y; Komatsu K; Koshida K; Namiki M
J Urol; 2003 Jan; 169(1):281-2. PubMed ID: 12478161
[No Abstract] [Full Text] [Related]
9. Molecular implications of the antiandrogen withdrawal syndrome.
Moul JW; Srivastava S; McLeod DG
Semin Urol; 1995 May; 13(2):157-63. PubMed ID: 7543690
[No Abstract] [Full Text] [Related]
10. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
[TBL] [Abstract][Full Text] [Related]
11. Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.
Krongrad A; Brady J; Rodriguez RJ
South Med J; 1997 Apr; 90(4):460-1. PubMed ID: 9114847
[No Abstract] [Full Text] [Related]
12. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.
Paul R; Breul J
Drug Saf; 2000 Nov; 23(5):381-90. PubMed ID: 11085345
[TBL] [Abstract][Full Text] [Related]
13. [Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
Barthélémy Y; Colombel M; Gasman D; Patard JJ; Chopin D; Abbou CC
Prog Urol; 1996 Feb; 6(1):93-7. PubMed ID: 8624534
[TBL] [Abstract][Full Text] [Related]
14. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
15. Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.
Laufer M; Sinibaldi VJ; Carducci MA; Eisenberger MA
Urology; 1999 Oct; 54(4):745. PubMed ID: 10754148
[TBL] [Abstract][Full Text] [Related]
16. Metastatic prostate cancer with a normal prostate-specific antigen level.
Ruiz-Martín I; Rodríguez-Sánchez CA; Ocaña-Fernández A; del Valle-Zapico J; Soto de Prado-Otero D; Cruz-Hernández JJ
Clin Transl Oncol; 2005 Oct; 7(9):412-3. PubMed ID: 16238977
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
18. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Takeshita H; Kawakami S; Fukui I
Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
[No Abstract] [Full Text] [Related]
19. Prostate cancer: an enzalutamide antiandrogen withdrawal syndrome.
Phillips R
Nat Rev Urol; 2014 Jul; 11(7):366. PubMed ID: 24960596
[No Abstract] [Full Text] [Related]
20. [PSA and hormone-refractory period in prostatic cancer].
Ojea Calvo A; Verez M; Alonso A; Rodríguez B; Domínguez F; Benavente J; Barros JM; Nogueira March JL
Actas Urol Esp; 1996 Feb; 20(2):168-71. PubMed ID: 8677815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
